Superparamagnetic iron oxide nanoparticles: Amplifying ros stress to improve anticancer drug efficacy

Theranostics

Volumn 3, Issue 2, 2013, Pages 116-126

  Huang, Gang ^a   Chen, Huabing ^a   Dong, Ying ^a   Luo, Xiuquan ^a   Yu, Haijun ^a   Moore, Zachary ^a   Bey, Erik A ^a   Boothman, David A ^a   Gao, Jinming ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

lapachone; Fenton reaction; Reactive oxygen species; Superparamagnetic iron oxide nanoparticles; Theranostic nanomedicine

Indexed keywords

BETA LAPACHONE; CATALASE; REACTIVE OXYGEN METABOLITE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; FERRIC ION; FERRIC OXIDE; NANOPARTICLE; NAPHTHOQUINONE; OXIDIZING AGENT;

ACIDITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG UPTAKE; FENTON REACTION; IRON KINETICS; LUNG NON SMALL CELL CANCER; MICELLE; OXIDATIVE STRESS; DRUG EFFECT; EPITHELIUM CELL; HUMAN; MAGNETISM; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; THERANOSTIC NANOMEDICINE.; TUMOR CELL LINE; Β-LAPACHONE;

FENTON REACTION; REACTIVE OXYGEN SPECIES; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; THERANOSTIC NANOMEDICINE.; Β-LAPACHONE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPITHELIAL CELLS; FERRIC COMPOUNDS; HUMANS; MAGNETICS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NAPHTHOQUINONES; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

MLCS; MLOWN;

EID: 84879001386     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5411     Document Type: Article

References (52)

1. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discovery Technol. 2009; 6: 43-51.
2. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008; 29: 3583-90.
3. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011; 44: 883-92.
4. Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater. 2010; 22: 2729-42.
5. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11: 2319-31.
6. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008; 60: 1252-65.
7. Shubayev VI, Pisanic Ii TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009; 61: 467-77.
8. Ai H, Flask C, Weinberg BD, Shuai X, Pagel MD, Farrell D, et al. Magnetite-loaded polymeric micelles as novel magnetic resonance probes. Adv Mater. 2005; 17: 1949-52.
9. Kessinger CW, Khemtong C, Togao O, Takahashi M, Sumer BD, Gao J. In vivo angiogenesis imaging of solid tumors by alpha(v)beta(3)-targeted, dual-modality micellar nanoprobes. Exp Biol Med (Maywood). 2010; 235: 957-65.
10. Kessinger CW, Togao O, Khemtong C, Huang G, Takahashi M, Gao J. Investigation of in vivo targeting kinetics of alpha(v)beta(3)-specific superparamagnetic nanoprobes by time-resolved MRI. Theranostics. 2011; 1: 263-73.
11. Khemtong C, Kessinger CW, Ren JM, Bey EA, Yang SG, Guthi JS, et al. In vivo off-resonance saturation magnetic resonance imaging of alpha(v)beta(3)-targeted superparamagnetic nanoparticles. Cancer Res. 2009; 69: 1651-8.
12. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006; 6: 2427-30.
13. Guthi JS, Yang SG, Huang G, Li S, Khemtong C, Kessinger CW, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm. 2010; 7: 32-40.
14. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011; 63: 24-46.
15. Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 2005; 18: 383-9.
16. Lin M, Kim HH, Kim H, Muhammed M, Kyung Kim D. Iron oxide-based nanomagnets in nanomedicine: fabrication and applications. Nano Rev. 2010; 1: 4883.
17. Pouliquen D, Lejeune JJ, Perdrisot R, Ermias A, Jallet P. Iron-oxide nanoparticles for use as an MRI contrast agent - pharmacokinetics and metabolism. Magn Reson Imaging. 1991; 9: 275-83.
18. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 2003; 229: 838-46.
19. Gao J, Gu H, Xu B. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res. 2009; 42: 1097-107.
20. Skotland T, Sontum PC, Oulie I. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan(TM)), a contrast agent for magnetic resonance imaging. J Pharm Biomed Anal. 2002; 28: 323-9.
21. Yang CY, Hsiao JK, Tai MF, Chen ST, Cheng HY, Wang JL, et al. Direct labeling of hMSC with SPIO: the long-term influence on toxicity, chondrogenic differentiation capacity, and intracellular distribution. Mol Imaging Biol. 2011; 13: 443-51.
22. Schlorf T, Meincke M, Kossel E, Gluer CC, Jansen O, Mentlein R. Biological properties of iron oxide nanoparticles for cellular and molecular magnetic resonance imaging. Int J Mol Sci. 2010; 12: 12-23.
23. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989; 152: 167-73.
24. Kolter T, Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett. 2010; 584: 1700-12.
25. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011; 434: 365-81.
26. Goldstein S, Meyerstein D, Czapski G. The Fenton reagents. Free Radic Biol Med. 1993; 15: 435-45.
27. Puzyn T, Rasulev B, Gajewicz A, Hu X, Dasari TP, Michalkova A, et al. Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. Nat Nanotechnol. 2011; 6: 175-8.
28. Brillas E, Sires I, Oturan MA. Electro-Fenton process and related electrochemical technologies based on Fenton's reaction chemistry. Chem Rev. 2009; 109: 6570-631.
29. Voinov MA, Pagan JO, Morrison E, Smirnova TI, Smirnov AI. Surface-mediated production of hydroxyl radicals as a mechanism of iron oxide nanoparticle biotoxicity. J Am Chem Soc. 2010; 133: 35-41.
30. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discovery. 2009; 8: 579-91.
31. Cabello CM, Bair WB, 3rd, Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs. 2007; 8: 1022-37.
32. Fry FH, Jacob C. Sensor/effector drug design with potential relevance to cancer. Curr Pharm Des. 2006; 12: 4479-99.
33. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 2006; 16: 466-76.
34. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006; 98: 236-44.
35. Blanco E, Bey EA, Khemtong C, Yang S-G, Setti-Guthi J, Chen H, et al. β-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010; 70: 3896-904.
36. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang C-R, Girard L, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc Natl Acad Sci U S A. 2007; 104: 11832-7.
37. Gutteridge JM. Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. FEBS Lett. 1986; 201: 291-5.
38. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol. 2004; 5: 121-32.
39. Kon K, Kim JS, Uchiyama A, Jaeschke H, Lemasters JJ. Lysosomal iron mobilization and induction of the mitochondrial permeability transition in acetaminophen-induced toxicity to mouse hepatocytes. Toxicol Sci. 2010; 117: 101-8.
40. Sun SH, Zeng H, Robinson DB, Raoux S, Rice PM, Wang SX, et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc. 2004; 126: 273-9.
41. Zhou K, Wang Y, Huang X, Luby-Phelps K, Sumer BD, Gao J. Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew Chem -Int Edit. 2011; 50: 6109-14.
42. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem. 2000; 275: 5416-24.
43. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev. 2009; 61: 768-84.
44. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem. 2006; 281: 33684-96.
45. Khaket TP, Ahmad R. Biochemical studies on hemoglobin modified with reactive oxygen species (ROS). Appl Biochem Biotech. 2011; 164: 1422-30.
46. Richardson DR, Ponka P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol. 1998; 58: 299-305.
47. Abu-Murad C, Nordmann R. Effect of two iron-chelators, desferrioxamine and diethylenetriaminepentaacetic acid, on the development of tolerance to the physical dependence on ethanol in mice. Drug Alcohol Depend. 1983; 12: 371-9.
48. Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res. 2010; 70: 8088-96.
49. Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res. 2007; 67: 6936-45.
50. Gao L, Zhuang J, Nie L, Zhang J, Zhang Y, Gu N, et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol. 2007; 2: 577-83.
51. Hartz JW, Funakoshi S, Deutsch HF. The levels of superoxide dismutase and catalase in human tissues as determined immunochemically. Clin Chim Acta. 1973; 46: 125-32.
52. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem. 1998; 273: 7382-9.